Suppliers / Strides Pharma Science

Strides Pharma Science

India 3 duplicate records merged Updated 9 July 2026

Strides Pharma Science is a finished-dose manufacturer based in India. It appears in 88 regulatory filings across 12 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, EFDA (ET) and NCELS (KZ). Its GMP standing is certified by EMA, CDSCO (India) and MHRA (UK), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 5 April 2024 as VAI. Customs aggregates show $247.1M of exports covering 3,798 molecules to 63 destinations in 2025.

0
active US DMFs
0
valid CEPs
9
registered plants 3 with an FDA FEI number
88
filings across 12 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 5 April 2024 VAI US FDA
  • 24 February 2023 VAI US FDA
  • 9 December 2022 VAI US FDA
  • 5 March 2020 NAI US FDA
  • 17 January 2020 VAI US FDA
  • 9 August 2019 NAI US FDA
  • 24 May 2019 VAI US FDA
  • 5 February 2019 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Bangalore, United Arab Emirates Not on file
BANGALORE, India Not on file
PUDUCHERRY, India Not on file
Bengaluru, India 3004554612
bengaluru 560 099, India Not on file
Periyakalapet, India 3012448465

3 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 48 1
EFDA (ET) 6 None
NCELS (KZ) 6 None
TMDA (TZ) 5 None
UZPHARM (UZ) 5 None
ZAMRA (ZM) 4 None
EMA None 5
CDSCO (India) None 4
MHRA (UK) None 2
NAFDAC (NG) None 2
ANVISA (Brazil) None 1

Scale

Year Revenue Exports Destinations
2025 Not reported $247.1M 63
2024 Not reported $253.8M 69
2023 Not reported $245.2M 74
2022 Not reported $224.0M 86

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Strides Pharma Science comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 5 April 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts